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Abstract Apoptosis, or programmed cell death, plays a central
role in the development and homeostasis of an organism. The
breakdown of cellular proteins in apoptosis is mediated by
caspases, which comprise a highly conserved family of cysteine
proteases with specificity for aspartic acid residues at the P1
positions of their substrates. Multiple lines of evidence show that
caspase-9 is critical for an apoptosis pathway mediated via the
mitochondria. In this study, the three-dimensional structure of
the catalytic domain of caspase-9 and its interaction with the
inhibitor acetyl-Asp-Val-Ala-Asp fluoromethyl ketone (Ac-
DVAD-fmk) have been predicted by a segment matching
modeling procedure. As expected, the predicted caspase-9
structure shows both a high similarity in the overall folding
topology and remarkable differences in the surface loop regions
as compared to other caspase family members such as caspase-1,
-3 and -8, for which crystal structures have been determined. This
kind of comparative analysis reflects the convergence^divergence
duality among the caspases. Moreover, some subtle differences
have been observed between caspase-9 and caspase-3 in the
subsite contacts with the covalently linked inhibitor Ac-DVAD-
fmk. Based on the X-ray structural analysis of caspase-8, a main
chain carbonyl oxygen appears to be involved in a catalytic triad
with the active site Cys and His residues. The corresponding
carbonyl oxygen in caspase-9, together with other expected
features of the catalytic apparatus, appears in our model. The
predicted structure of caspase-9 can serve as a reference for
subsite analysis relative to rational design of highly selective
caspase inhibitors for therapeutic application.
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1. Introduction
Apoptosis, also known as programmed cell death or cellular
suicide, plays a central role in development and homeostasis
of an organism [1,2] and is currently an area of intense inves-
tigation. Unlike human beings committing suicide that almost
always leads to a tragedy, the normal function of cellular
suicide within the organism is vital to life. It serves to prune
tissues during embryonic development and provides a mech-
anism for removal of damaged cells in the adult in a neat,
orderly way. In normal animal development, cell death is in-
volved not only in morphogenesis, but also in optimizing
function in the immune and central nervous systems. Cell
death and renewal are responsible for maintaining the proper
turnover of cells, which ensures a constant controlled £ux of
fresh cells. Programmed cell death and cell proliferation are
tightly coupled. When apoptosis malfunctions, a variety of
formidable diseases can ensue: blocking apoptosis is associ-
ated with cancer [3,4] and autoimmune diseases, while un-
wanted apoptosis can possibly lead to ischemic damage [5^
7] or neurodegenerative disease [8^10]. Apoptosis is consid-
ered to play a key role in these several devastating diseases
and, in principle, provides many targets for therapeutic inter-
vention [11].
The question as to how cells die in an organized, non-ne-
crotic fashion has intrigued biologists for decades. Most apop-
totic processes are mediated through caspases although cas-
pase-independent apoptosis does exist [12,13]. The activation
of caspases (cysteinyl aspartate-speci¢c proteases) is a key
event in the induction of programmed cell death, as it initiates
a cascade of cleavage reactions that contribute to the disrup-
tion of structural components within the cell, as well as the
disabling of critical repair processes. While detailed structural
analyses have not been performed for all caspases, amino acid
sequence alignments demonstrate that caspases comprise a
highly conserved family of cysteine proteases with speci¢city
for aspartic acid residues in their substrates [14^17]. It is the
cleavage of key substrates by these caspases that orchestrates
the organized and e⁄cient packaging of the cells for clear-
ance. Accordingly, apoptosis is actually a process of cas-
pase-mediated cell death. In view of this, caspase inhibitors
might represent e¡ective new drugs against Alzheimer’s dis-
ease, and other incurable degenerative disorders where it is
desirable to block apoptosis [18]. The rational design of
such caspase inhibitors will require detailed structural infor-
mation concerning their catalytic sites and modes of ligand
binding.
The three-dimensional (3-D) structures of caspase-1 (also
called interleukin converting enzyme (ICE)) and caspase-3
(also called apopain or CPP32) have been determined by
X-ray crystallography [19^21]. The 3-D structure of caspase-
8 (also called FLICE) was ¢rst predicted by computer model-
ing [22], and later determined at atomic resolution by X-ray
crystallography [23,24]. The predicted 3-D structure of cas-
pase-8 and the corresponding X-ray structure are very close,
especially in the core of the structure (root mean square de-
viation (RMS) = 1.2 Aî ).
Caspase-9 is another of the initiating, or upstream activator
caspases which lead to production of the downstream execu-
tioners of apoptosis such as caspase-3. However, the 3-D
structure of caspase-9 has not as yet been reported. Although
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caspase-8 can lead directly to downstream caspase activation
in certain cell types, and with appropriate death stimuli, mi-
tochondria are the essential mediators in others [25]. Actually,
mitochondrial damage is a major ampli¢cation step in the
apoptotic pathway [26], and caspase-9 is the central initiator
that works in conjunction with cytochrome c, Apaf-1 and
dATP to activate the downstream caspases-3, -6 and -7
[27,28]. Recently, a model for caspase-9 recruitment to the
Apaf-1 complex via caspase recruitment domain (CARD)/
CARD interactions was derived, based on the nuclear mag-
netic resonance (NMR)-determined CARD structure of the
RIP-associated ICH-1 with a death domain (RAIDD) adap-
tor protein [28,29]. Interestingly, multiple lines of evidence
show that caspase-9 activation also serves as an ampli¢cation
step in the Fas/TNF-induced apoptosis pathway via caspase-
8. Upon cleavage by caspase-8, BID, a pro-apoptosis regula-
tory protein, is able to induce cytochrome c release and there-
by activate caspase-9 [26,30]. The 3-D solution structure of
BID [31] and the solution structure of Apaf-1 CARD and its
interaction with caspase-9 CARD [32] were recently deter-
mined by NMR. A recent report further con¢rms that cas-
pase-9 is critical for cytochrome c-dependent apoptosis and
normal brain development [6]. Although the details of how
procaspase-9 becomes activated are not known, mutations in
caspase-9 result in embryonic lethality with a much enlarged
and malformed cerebrum similar to that seen in caspase-3
knockout mice [33,34]. In view of the importance of the cas-
pase-9 pathway in mediating the apoptotic response, it is of
considerable interest to gain insights into the tertiary structure
of this enzyme. The current study describes the modeling of
the 3-D structure of the protease domain of caspase-9 in com-
plexation with the inhibitor acetyl-Asp-Val-Ala-Asp £uoro-
methyl ketone (Ac-DVAD-fmk).
2. Materials and methods
The sequence of caspase-9 (also called ICE-LAP6) was taken from
Duan et al. [35] and Srinivasula et al. [36]. It was found by running a
BLAST search [37,38] that, among proteins of known 3-D structure,
caspase-3 had the highest score bits in sequence similarity with cas-
pase-9. It was indicated by running BESTFIT in the GCG package
[39] that the sequence similarity between the two enzymes was 50.7%.
Accordingly, the X-ray structure of caspase-3 determined by Mittl et
al. [21] was selected as a template to predict the 3-D structure of
caspase-9. The sequences of caspase-3 and caspase-9 were aligned
using the PILEUP program in the GCG package [39]. The aligned
result is given in Fig. 1, where the amino acid sequences in black
boxes represent the protease domain whose atomic coordinates were
Fig. 1. Alignment of the amino acid sequences of caspase-3 and caspase-9 using PILEUP in the GCG package [39]. The amino acids in the
black box for caspase-3 are de¢ned by X-ray coordinates [21]; those for caspase-9 are predicted in the present study. The amino acids brack-
eted are the conserved active site pentapeptide segments for the caspase family [48,49].
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either determined by X-ray crystallography, as for the case of caspase-
3 [21], or are to be predicted as done here for caspase-9. In the
domain comparisons, the A- and B-chains of caspase-3 comprise res-
idues 35^173 and residues 185^277, respectively, and for caspase-9,
residues 151^297 and 332^405, respectively.
Based on the sequence alignment (Fig. 1) and the X-ray coordinates
of caspase-3, the protease domain of caspase-9 was predicted. Mean-
while, based on the coordinates of the tetrapeptide Ac-DVAD-CH2 in
the caspase-3:Ac-DVAD-CH2 complex, the binding site of the inhib-
itor to caspase-9 was also located. In the present study, the segment
matching modeling method [40] was adopted to compute the protease
domain of caspase-9. This method uses a database of known protein
structures to build an unknown target structure from the amino acid
sequence. The target structure is ¢rst broken into a set of short seg-
ments. The database is then searched for matching segments on the
basis of amino acid sequence similarity and compatibility with the
target structure. The process is repeated 10 times and an average
model is generated, followed by energy minimization to create the
¢nal model. This procedure was originally shown to be highly accu-
rate for eight test proteins ranging in size from 46 to 323 residues,
where the all-atom RMS deviation of the modeled structures is be-
tween 0.93 Aî and 1.73 Aî [40]. This method was used to model the
structure of the protease domain of caspase-8 at a time before the X-
ray coordinates were released for caspase-3 [22]. First, the atomic
coordinates of the catalytic domain of caspase-3 were predicted based
on the X-ray structure of caspase-1, and then the caspase-3 structure
thus obtained served as a template to model the protease domain of
caspase-8. After the X-ray coordinates of caspase-3 protease domain
were ¢nally released and the X-ray structure of the caspase-8 protease
domain determined [23], it turned out that the RMS for all the back-
bone atoms of the caspase-3 protease domain between the X-ray and
predicted structures is 2.7 Aî , and the corresponding RMS is 3.1 Aî for
caspase-8 and only 1.2 Aî for its core structure. This indicates that the
computed structures of caspase-3 and -8 were quite close to the cor-
responding X-ray structures. Recently, this method was applied to
model the CARDs of Apaf-1, caspase-9, Ced-4 and Ced-3, based on
the NMR structure of the RAIDD CARD [29], and for TPKII (Tau
protein kinase) [41] based on the X-ray structure of the Cdk2^cyclin
A^ATP complex.
The computed structure now obtained for caspase-9 was further
re¢ned by energy minimization with respect to all the side-chains
using AMBER (assisted model building with energy re¢nement) force
¢eld [42]. An examination by ProCheck [43] for the current model has
indicated its rationality from the structural point of view.
3. Results and discussion
The predicted 3-D structure of caspase-9 is illustrated in
Fig. 2.
3.1. Overall structure
The structure of caspase-9 consists of the A-chain (yellow)
and B-chain (burgundy) comprising residues 151^297 and
333^416, respectively (Figs. 1 and 2). The two polypeptide
chains associate to form a heterodimer, which folds into one
compact structure of a single domain with an overall dimen-
sion of V26 AîU37 AîU39 Aî and a solvent accessible surface
of V11 918 Aî 2. The two subunits interact extensively and are
tethered to each other by 28 hydrogen bonds. The approxi-
mate area of the solvent accessible interface between the two
subunits is 3590 Aî 2. As expected, the overall topology is sim-
ilar to that of caspase-1, caspase-3 and caspase-8, with a typ-
ical K/L folding motif. The core of the enzyme is formed by a
central 6-stranded L-sheet (Fig. 2), of which four strands (L1,
residues 160^168; L2, 199^206; L3, 228^236; L4, 279^286) are
donated from the A-chain and two (L5, residues 340^347; L6,
411^416) from the B-chain. Except for L6, the ¢rst ¢ve strands
are all parallel. Consistent with the handedness of L-sheets
observed in proteins [44], the L-sheet in the predicted cas-
pase-9 structure assumes a right-handed twist, a result dic-
tated by energetic optimization [45,46]. The L-sheet is sur-
rounded by ¢ve K-helices: two (K2, residues 208^222; K3,
259^268) are located on one side of the sheet, and three
(K1, residues 182^198; K4, 361^377; K5, 379^393) on the oth-
Fig. 2. Schematic representation of the caspase-9:Ac-DVAD-CH2
complex. The ribbon drawing is used for the heterodimer enzyme,
where the A-chain is colored yellow and the B-chain burgundy. The
inhibitor is represented by a ball and stick drawing.
Fig. 3. A backbone superimposition of the X-ray crystallographic
structures of caspase-1 (blue), caspase-3 (green) and caspase-8 (yel-
low), and our predicted structure of caspase-9 (red).
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er side. Helices K1, K2 and K3 belong to the A-chain, and
helices K4 and K5 to the B-chain. The loop between L3 and
K3 contains a minor L-sheet formed by two short antiparallel
L-strands, L13 (residues 238^242) and L
2
3 (residues 246^250).
The loop between K5 and L6 contains a very short K-helix,
K13 (residues 402^405). As is the case with other caspase family
members, the C-terminus of the A-chain and the N-terminus
of the B-chain lie at opposite ends of the molecule (Fig. 2);
these segments appear to play a role in the formation of
protease heterotetramers.
Finally, to provide an overall illustration of the general
similarity and subtle di¡erences among the 3-D structures of
caspase-1, caspase-3, caspase-8 and caspase-9, a backbone
superimposition of the four enzymes is given in Fig. 3, where
caspase-1 is colored blue, caspase-3 green, caspase-8 yellow
and caspase-9 red. As we can see from the superimposed
picture, although the general folding topology of the four
structures is quite similar, there are many di¡erences in their
surface loop regions that are actually caused by the existence
of insertions or deletions in amino acids [22]. Just as in the
Fig. 4. The binding interaction between the covalently bound inhibitor Ac-DVAD-CH2 and caspase-9. P1, P2, P3 and P4 residues of the inhibi-
tor are colored red, yellow, light blue and green, respectively. The relevant residues of the enzyme are colored white; hydrogen bonds are repre-
sented by yellow dotted lines. The interaction is featured by a covalent thioether bond between the methylene C of the P1 Asp residue and S-Q
of Cys-287, as well as the 12 hydrogen bonds as detailed in Table 1. Only heavy atoms and the hydrogen atoms attached to the hetero-atoms
are shown.
Table 1
Hydrogen bond interactions between caspase-9 and Ac-DVAD-CH2
Subsitea Atom in Ac-DVAD-CH2 Atom in caspase-9 Distance (Aî )
S4 Asp-1 O-N1 Trp-362 N-O 2.64
Asp-1 O Gln-399 N-O2 2.70
S3 Val-2 N Arg-355 O 2.95
Val-2 O Arg-355 N 2.84
S2
S1 Asp-4 O-N1 Arg-180 N-O 2.81
Asp-4 O-N2 Arg-180 N-R2 2.82
Asp-4 O Gly-238 N 3.02
Asp-4 O-N2 Gln-285 N-O2 2.74
Asp-4 O Cys-287 N 3.32
Asp-4 N Ser-353 O 2.98
Asp-4 N Arg-355 O 2.95
Asp-4 O Arg-355 N 2.84
aThe subsite symbol and order proposed by Schechter and Berger [48] are adopted here.
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case of lectin domains in the selectin family [47], this kind of
similarity and di¡erence re£ects the convergence^divergence
duality in the catalytic domains of the caspase family. Partic-
ularly, it is the di¡erence in the loop regions near the active
site that may be of use for rationally designing caspase inhib-
itors with a highly selective speci¢city.
3.2. Inhibitor binding
Right above the end of the L4 strand (Fig. 2), there is a
deep cavity of V9 AîU8 AîU 16Aî , where the tetrapeptide
inhibitor moiety, acetyl-Asp-Val-Ala-Asp-CH2, is bound to
the active site thiol of the enzyme. The approximate area of
the solvent accessible interface between the enzyme and the
inhibitor is 864 Aî 2. The detailed binding interaction between
the predicted caspase-9 catalytic domain and the tetrapeptide
inhibitor is shown in Fig. 4, where the hydrogen bonds be-
tween the enzyme and the inhibitor are shown by the yellow
dotted lines and the two atoms that form the irreversible co-
valent bond (the thioether bond) by two pink arrows. There
are a total of 12 hydrogen bonds that tether the inhibitor to
the enzyme. An examination of the binding interaction for
each of the four subsites of the tetrapeptide inhibitor led to
the following information (the subsite symbol and order fol-
low the expression proposed originally by Schechter and Berg-
er [48]). (1) S4 pocket: there are two hydrogen bonds that
tether the ¢rst residue of the tetrapeptide inhibitor, Asp-1 or
P4, to the residues Trp-362 and Gln-399 of the enzyme. (2) S3
pocket: two hydrogen bonds are formed that hold the P3 Val-
2 to Arg-355 of the enzyme. (3) S2 pocket: there is no hydro-
gen bond between the third residue of the inhibitor, Ala-3 or
P2, and the enzyme, which is exactly the same as observed in
the X-ray structure for the caspase-3:inhibitor complex [21].
This is very likely due to the small size of the Ala side-chain.
If the P2 Ala is replaced with a large side-chain residue, such
as in the caspase-3:Ac-DEVD-CH2 complex, two hydrogen
bonds have been observed that tether Val-3 to the enzyme
[20]. (4) S1 pocket: the most hydrogen bonds are formed in
this pocket, just as in the case of caspase-3:inhibitor complex
[21]. There are eight hydrogen bonds formed in this pocket
that tether the fourth residue of the tetrapeptide inhibitor,
Asp-4 or P1, to the residues Arg-180, Gly-238, Gln-285,
Cys-287, Ser-353 and Arg-355 of the enzyme. As shown in
Fig. 5. A schematic illustration of the similarity and di¡erence of
the hydrogen bonding interaction with the tetrapeptide inhibitor Ac-
DVAD-CH2 in (a) caspase-9 complex and (b) caspase-3 complex.
Counterparts of the inhibitor P1^P4 residues are represented by the
enzyme subsites, S1, S2, S3 and S4, respectively. Each of such four
S^P pairs has a zigzag line with a ¢gure to indicate the number of
the corresponding hydrogen bonds therein. Residues in S1 and S3
are spatially equivalent in the two enzymes; in S4, only the Trp res-
idues are equivalent.
Table 2
Hydrogen bond interactions between the amino acids in the conservative pentapeptide QACXG and the other part of the enzyme for each of
the four caspase members
Caspase member Atom in the amino acid in the conservative
QACXG pentapeptide
Atom in the other part
of the enzyme
Distance (Aî )
Caspase-1, X = Arg-286 Gln-283 N Phe-234a O 3.05
Gln-283 O Ser-236b N 2.85
Arg-286 N Glu-390 O-O2 2.18
Caspase-3, X = Arg-164 Gln-161 N Leu-118a O 3.01
Gln-161 O Ser-120b N 3.14
Gln-161 N-O2 Ser-205 O-Q 2.65
Arg-164 O Gly-202 N 2.64
Arg-164 N Tyr-203c O 3.00
Arg-164 N-R2 Glu-124d O-O2 2.86
Caspase-8, X = Gln-361 Gln-358 N Ile-314a O 2.83
Gln-358 O Ser-316b N 2.94
Gln-361 N-O2 Ile-322 O 2.98
Gln-361 N-O2 Cys-360 O 2.93
Gln-361 O-O1 Gly-321 N 2.93
Caspase-9, X = Gly-288 Gln-285 N Ile-234a O 2.88
Gln-285 O Ser-236b N 2.96
Gln-285 O-O1 Lys-410 N-j 2.77
Ala-286 N Ser-346 O-Q 2.75
Gly-288 N Phe-351c O 2.93
Gly-288 O Gln-240d N-O2 2.72
Amino acid residues with a same superscript are equivalent to one another in position according to the sequence alignment of the four caspases
(see Figs. 1 and 3 of Chou et al. [22] and Fig. 1 of this paper).
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Fig. 4 and Table 1, Arg-355 alone contributes four hydrogen
bonds in binding the inhibitor: two for P3 and two for P1.
Accordingly, Arg-355 could be an excellent candidate for mu-
tagenesis studies. The detailed atom pairs that are involved in
forming these hydrogen bonds and their distances are given in
Table 1. To facilitate the comparison between caspase-9 and
caspase-3 in inhibitor binding, the hydrogen bonding interac-
tion between the inhibitors and the enzymes in each of the
four subsites is shown schematically in Fig. 5a,b. As we can
see from Fig. 5, although some di¡erences exist between cas-
pase-9 and caspase-3 in the S4 subsite, the interactions in S3,
S2 and S1 are identical. Also, as in the case of the caspase-
3:inhibitor complex [21], there is an alkyl thioether bond, that
tightly binds the methylene carbon of the P1 Asp to Cys-287
of the enzyme. The distance predicted between this methylene
carbon atom of the inhibitor and the atom S-Q of Cys-287 of
the enzyme is 1.81 Aî , which is exactly the same as that seen in
the X-ray structure of the caspase-3:inhibitor complex.
3.3. The conserved pentapeptide segment QACXG
The pentapeptide segments as bracketed in Fig. 1 is highly
conserved among caspase family members as generally ex-
pressed by QACXG [36,49]. For caspase-1 and -3, it is
QACRG, for caspase-8, QACQG, and for caspase-9,
QACGG. As pointed out by Alnemri [50], while the overall
amino acid sequence identity varies from about 25% to 55%
among caspases, the active sites of all caspase family members
contain the conserved pentapeptide sequence QACXG, sug-
gesting that the catalytic mechanism is conserved. It is inter-
esting to note that among all known caspases to date, only
caspase-9 has a Gly residue as X in the pentapeptide sequence.
The absence of a side-chain at this position in caspase-9 sug-
gests more £exibility in the active site region and, indeed,
more access to conformational space. It is of interest, there-
fore, to note the environment of the QACXG region, and in
particular of the X-residue, in the various solved caspase
structures. In Table 2 is given an array of H-bond contacts
seen in the QACXG residues in the three solved caspase/in-
hibitor complexes, and in the predicted caspase-9 structure.
The ¢rst Gln residue shows identical interactions in caspase-
1, -3 and -8 involving amide to carbonyl H-bonds; these are
formed among homologous regions in the chains. These same
interactions are predicted in caspase-9. In caspase-3, the Gln
amide is hydrogen-bonded to the side-chain oxygen of Ser-
205. We predict a di¡erent additional H-bond involving the
side-chain carbonyl oxygen of the Gln and the N-O of Lys-
Fig. 6. Illustration to show the relative position of the inhibitor Ac-DVAD-CH2, the conserved pentapeptide QACGG and the catalytic triad
of caspase-9. The inhibitor is colored white, and the three components of the catalytic triad are highlighted by red. The dotted line is used to
mark the 2.78 Aî distance between the backbone carbonyl oxygen of Arg-178 and the N-O2 of His-237. Only heavy atoms and the hydrogen
atoms attached to the hetero-atoms are shown.
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410. The Cys and ¢nal Gly of the conserved pentapeptide
sequence show no di¡erences among the four caspases. Of
interest is the Ala, which in our caspase-9 model alone shows
a H-bond interaction between the amide and the O-Q of Ser-
346. Located two residues away is the X-residue, a Gly in
caspase-9. Since the pentapeptide QACXG has an extended
conformation, the side-chains of every other residues along
the peptide, such as A and X, are even closer than those of
two consecutive ones. Thus, the absence of a side-chain at the
residue X, Gly-288, provides a space for access of the side-
chain of Ser-346 to form a hydrogen bond with Ala-286,
which is an unique feature for caspase-9. The X-residue in
caspase-9, Gly-288, is pinned down by two H-bonds involving
its main chain amide and carbonyl oxygen; the former is with
the carbonyl oxygen of Phe-351. This corresponds to a similar
H-bond seen in the X-residue of caspase-3, i.e. Arg-164, in
which the main chain amide is linked to the carbonyl oxygen
of the homologous Tyr-203. Interactions seen between the
side-chains of the X-residues and portions of the respective
enzymes are variable and di⁄cult to interpret. A general pic-
ture does not emerge from the structural comparisons, but it
would appear that the space around the fourth Gly residue in
the caspase-9 model can be partially ¢lled by the insertion of
the side-chains of Ser-346 and Thr-347. These changes may,
therefore, represent a compensation for the small X-residue in
caspase-9.
3.4. A catalytic triad
Wilson et al. [19] proposed the Cys-His catalytic dyad for
caspase-1, but indicated the possible involvement of a putative
third component, the backbone carbonyl oxygen of Pro-177,
that could a¡ect the basicity of the histidine imidazole. For
the case of caspase-3, Rotonda et al. [20] invoked the existence
of the same carbonyl oxygen of Thr-62 that might play the
same role as that of Pro-177 in caspase-1. Since no clear
evidence was provided about the third component, Mittl et
al. [21] suggested that the ICE-like proteases have a catalytic
Cys-His dyad instead of the classical Cys-His-Asn triad as
found in papain and most other cysteine proteases. Recently,
based upon the atomic resolution structure of caspase-8, it
was observed [23] that the distance between the carbonyl oxy-
gen of Arg-258 and the N-O2 of His-317 is 2.74 Aî , which is
smaller than 3 Aî and hence indicates a clear interaction be-
tween these two atoms. Arg-258 in caspase-8 is equivalent to
Pro-177 in caspase-1 and Thr-62 in caspase-3. Accordingly,
Watt et al. [23] inferred that, irrespective of the nature of
the amino acid at this position, the carbonyl oxygen can serve
as a member of a catalytic triad in the caspases. Actually, even
in the earlier computed structure [22] of caspase-8, it was
found that the distance between the carbonyl oxygen of
Arg-258 and the N-O2 of His-317 is 2.96 Aî (i.e. also 6 3
Aî ), suggesting a possible salt bridge interaction as well. The
current model of caspase-9 further supports such an inference.
As shown in Fig. 6, the distance between the carbonyl oxygen
of Arg-178 and N-O2 of His-237 is 2.78 Aî , implying that the
carbonyl oxygen of Arg-178 can serve as a member of a cata-
lytic triad in the caspase-9. According to the sequence align-
ment of Fig. 1 as well as the sequence alignments of Figs. 1
and 3 in Chou, K.C. et al. [22], Arg-178 of caspase-9 is equiv-
alent to Pro-177 of caspase-1, Thr-62 of caspase-3 and Arg-
258 of caspase-8; while His-237 in caspase-9 is equivalent to
His-237 in caspase-1, His-121 in caspase-3 and His-317 in
caspase-8. Except for the structure determined by Wilson et
al. [19] for caspase-1, in which the distance between the car-
bonyl oxygen of Pro-177 and N-O2 of His-237 is 3.24O, the
corresponding distances for all the other three caspases are
less than 3 Aî . It is anticipated that by improving the resolu-
tion in determining the X-ray structure, such a distance in
caspase-1 might also fall within the range of 3 Aî . Therefore,
it appears likely that caspases utilize a catalytic Cys-His-XbkO
triad mechanism, where XbkO represents the backbone car-
bonyl oxygen of any residue at the position of the third com-
ponent of the triad, irrespective of the nature of the amino
acid concerned: for caspase-1, it is Pro-177; for caspase-3,
Thr-62; for caspase-8, Arg-258; and for caspase-9, Arg-178.
Since caspase-9 has become increasingly important in the
study of apoptosis, the 3-D structure of caspase-9 as reported
here will further stimulate the study of this area. Particularly,
it can serve as a footing for thinking about design of inhib-
itors.
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